DDInter1936 DDInter782
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Vinblastine {u} (Compound) resembles {v} (Compound) Vindesine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinblastine {u} (Compound) treats {v} (Disease) kidney cancer
Vinblastine {u} (Compound) binds {v} (Gene) TUBB3
Vinblastine {u} (Compound) upregulates {v} (Gene) OSBPL2
Vinblastine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinblastine {u} (Compound) downregulates {v} (Gene) TMEM168
Vinblastine {u} (Compound) causes {v} (Side Effect) Paraesthesia
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Vinblastine (Compound) resembles Vindesine (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Vinblastine (Compound) treats kidney cancer (Disease)
Vinblastine (Compound) binds TUBB3 (Gene)
Vinblastine (Compound) upregulates OSBPL2 (Gene)
Vinblastine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinblastine (Compound) downregulates TMEM168 (Gene)
Vinblastine (Compound) causes Paraesthesia (Side Effect)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil